Published in Nat Commun on January 01, 2013
The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer (2013) 2.35
The proper criteria for identification and sorting of very small embryonic-like stem cells, and some nomenclature issues. Stem Cells Dev (2014) 1.70
Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol (2015) 1.65
Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther (2013) 1.44
Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget (2015) 1.21
New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med (2015) 1.12
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer Res (2015) 1.10
Contributions of the host microenvironment to cancer-induced bone disease. Cancer Res (2014) 1.07
Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases. Cancer Metastasis Rev (2014) 1.00
Molecular pathways and targets in prostate cancer. Oncotarget (2014) 1.00
The cancer diaspora: Metastasis beyond the seed and soil hypothesis. Clin Cancer Res (2013) 0.98
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. Proc Natl Acad Sci U S A (2014) 0.98
Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer (2013) 0.96
MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs. Proc Natl Acad Sci U S A (2014) 0.95
Induction of a tumor-metastasis-receptive microenvironment as an unwanted and underestimated side effect of treatment by chemotherapy or radiotherapy. J Ovarian Res (2013) 0.95
Mechanisms of T-cell immunosuppression by mesenchymal stromal cells: what do we know so far? Biomed Res Int (2014) 0.92
CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Rep (2015) 0.91
Cofilin drives cell-invasive and metastatic responses to TGF-β in prostate cancer. Cancer Res (2014) 0.89
Cancer-associated fibroblasts in digestive tumors. World J Gastroenterol (2014) 0.87
Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer (2016) 0.86
MitoCeption as a new tool to assess the effects of mesenchymal stem/stromal cell mitochondria on cancer cell metabolism and function. Sci Rep (2015) 0.86
CXCL12-γ in primary tumors drives breast cancer metastasis. Oncogene (2014) 0.84
Extracellular vesicles derived from renal cancer stem cells induce a pro-tumorigenic phenotype in mesenchymal stromal cells. Oncotarget (2015) 0.84
Very small embryonic-like stem-cell optimization of isolation protocols: an update of molecular signatures and a review of current in vivo applications. Exp Mol Med (2013) 0.83
Cancer-associated mesenchymal stem cells aggravate tumor progression. Front Cell Dev Biol (2015) 0.82
Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. Oncotarget (2016) 0.81
The Multiple Roles of Exosomes in Metastasis. Cancer Genomics Proteomics (2016) 0.81
Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow. Mol Cancer Res (2014) 0.81
PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis. Carcinogenesis (2014) 0.81
Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors. Bonekey Rep (2015) 0.81
CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nat Commun (2016) 0.81
Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures. Prostate (2016) 0.80
Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow. Oncotarget (2016) 0.80
The molecular nature of very small embryonic-like stem cells in adult tissues. Int J Stem Cells (2014) 0.80
Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma. Oncotarget (2015) 0.80
Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow. J Cell Biochem (2016) 0.79
Culture medium of bone marrow-derived human mesenchymal stem cells effects lymphatic endothelial cells and tumor lymph vessel formation. Oncol Lett (2015) 0.78
Neutrophils and Granulocytic MDSC: The Janus God of Cancer Immunotherapy. Vaccines (Basel) (2016) 0.78
Prostate cancer and bone: the elective affinities. Biomed Res Int (2014) 0.78
Targeted Proapoptotic Peptides Depleting Adipose Stromal Cells Inhibit Tumor Growth. Mol Ther (2015) 0.78
Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity. Connect Tissue Res (2015) 0.78
Concise Review: Pancreatic Cancer and Bone Marrow-Derived Stem Cells. Stem Cells Transl Med (2016) 0.77
Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. Nat Rev Drug Discov (2016) 0.77
DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis. Neoplasia (2016) 0.77
The role of chemoattractant receptors in shaping the tumor microenvironment. Biomed Res Int (2014) 0.77
Equine Arteritis Virus Uses Equine CXCL16 as an Entry Receptor. J Virol (2016) 0.77
Omentum and bone marrow: how adipocyte-rich organs create tumour microenvironments conducive for metastatic progression. Obes Rev (2016) 0.77
Scavenger Receptors: Emerging Roles in Cancer Biology and Immunology. Adv Cancer Res (2015) 0.77
Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression. Horm Cancer (2015) 0.77
Downregulation of CXCL12 in mesenchymal stromal cells by TGFβ promotes breast cancer metastasis. Oncogene (2016) 0.76
Disruption of crosstalk between mesenchymal stromal and tumor cells in bone marrow as a therapeutic target to prevent metastatic bone disease. J Cell Physiol (2014) 0.76
Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics. Transl Androl Urol (2015) 0.76
Characterization of stem-like cells in mucoepidermoid tracheal paediatric tumor. PLoS One (2014) 0.76
Inhibition of AQP1 Hampers Osteosarcoma and Hepatocellular Carcinoma Progression Mediated by Bone Marrow-Derived Mesenchymal Stem Cells. Int J Mol Sci (2016) 0.76
Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen. Clin Cancer Res (2016) 0.76
Lysosomal acid lipase in mesenchymal stem cell stimulation of tumor growth and metastasis. Oncotarget (2016) 0.75
Role of tumor microenvironment in tumorigenesis. J Cancer (2017) 0.75
Cancer cell-secreted IGF2 instigates fibroblasts and bone marrow-derived vascular progenitor cells to promote cancer progression. Nat Commun (2017) 0.75
Activated human mesenchymal stem/stromal cells suppress metastatic features of MDA-MB-231 cells by secreting IFN-β. Cell Death Dis (2016) 0.75
Recapitulating epithelial tumor microenvironment in vitro using three dimensional tri-culture of human epithelial, endothelial, and mesenchymal cells. BMC Cancer (2016) 0.75
Mesenchymal stem cell-conditioned medium promotes MDA-MB-231 cell migration and inhibits A549 cell migration by regulating insulin receptor and human epidermal growth factor receptor 3 phosphorylation. Oncol Lett (2017) 0.75
Allelic Variation in CXCL16 Determines CD3+ T Lymphocyte Susceptibility to Equine Arteritis Virus Infection and Establishment of Long-Term Carrier State in the Stallion. PLoS Genet (2016) 0.75
Cytokine signaling regulating adipose stromal cell trafficking. Adipocyte (2016) 0.75
Rat Prostate Tumor Cells Progress in the Bone Microenvironment to a Highly Aggressive Phenotype. Neoplasia (2016) 0.75
Role of stromal cell-derived factor 1α pathway in bone metastatic prostate cancer. J Biomed Res (2015) 0.75
Role of Aquaporin 1 Signalling in Cancer Development and Progression. Int J Mol Sci (2017) 0.75
Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery. J Control Release (2015) 0.75
Role of metabolic modulator Bet-CA in altering mitochondrial hyperpolarization to suppress cancer associated angiogenesis and metastasis. Sci Rep (2016) 0.75
Cell Connections by Tunneling Nanotubes: Effects of Mitochondrial Trafficking on Target Cell Metabolism, Homeostasis, and Response to Therapy. Stem Cells Int (2017) 0.75
Double-edged sword of mesenchymal stem cells: cancer-promoting VS therapeutic potentials. Cancer Sci (2017) 0.75
Mouse models of metastasis: progress and prospects. Dis Model Mech (2017) 0.75
Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung. Virchows Arch (2016) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A (1971) 31.05
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science (1999) 8.43
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature (2010) 5.43
How do stem cells find their way home? Blood (2005) 5.13
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res (2002) 5.00
Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle (2006) 4.67
The tumor microenvironment and its role in promoting tumor growth. Oncogene (2008) 4.66
Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell (2011) 3.83
Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell (2005) 3.68
Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res (2001) 3.48
A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol (2000) 3.44
The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem (2007) 3.38
Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med (2008) 2.97
Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev (2008) 2.95
Expression cloning of the STRL33/BONZO/TYMSTRligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol (2001) 2.12
The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci U S A (2009) 2.07
Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev (2010) 2.00
Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene (2004) 1.97
Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol (2003) 1.82
Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer (2004) 1.78
N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion withStromal cells. Am J Pathol (1999) 1.70
The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev (2006) 1.69
E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol (2001) 1.68
Mesenchymal stem cells: flip side of the coin. Cancer Res (2009) 1.66
Rapid and efficient homing of human CD34(+)CD38(-/low)CXCR4(+) stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2m(null) mice. Blood (2001) 1.62
CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell (2005) 1.41
Prospective identification and skeletal localization of cells capable of multilineage differentiation in vivo. Stem Cells Dev (2010) 1.38
Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis (2011) 1.35
CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J Biol Chem (2003) 1.34
CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res (2008) 1.33
The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One (2009) 1.29
Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. J Biol Chem (2011) 1.26
Ablation of proliferating marrow with 5-fluorouracil allows partial purification of mesenchymal stem cells. Stem Cells (2006) 1.26
CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer. Biochim Biophys Acta (2010) 1.23
Hit 'em where they live: targeting the cancer stem cell niche. Cancer Cell (2007) 1.23
Very small embryonic-like (VSEL) stem cells: purification from adult organs, characterization, and biological significance. Stem Cell Rev (2008) 1.19
CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res (2008) 1.18
S100 chemokines mediate bookmarking of premetastatic niches. Nat Cell Biol (2006) 1.17
Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. Cancer Res (2010) 1.15
Retracted The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation. Cancer Res (2008) 1.12
CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells. Cancer Sci (2008) 1.09
Critical role for CXC chemokine ligand 16 (SR-PSOX) in Th1 response mediated by NKT cells. J Immunol (2007) 1.05
Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma. Int J Oncol (2008) 1.05
Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients. Ann Surg Oncol (2011) 0.97
An alternatively spliced CXCL16 isoform expressed by dendritic cells is a secreted chemoattractant for CXCR6+ cells. J Leukoc Biol (2010) 0.95
Overexpression of CXCL16 and its receptor CXCR6/Bonzo promotes growth of human schwannomas. Glia (2008) 0.92
Clinical significance of CXCL16/CXCR6 expression in patients with prostate cancer. Mol Med Rep (2011) 0.90
Mesenchymal niches of bone marrow in cancer. Clin Transl Oncol (2011) 0.81
Adhesion molecules expression as a potential marker of prostate cancer aggressivity. A TMA study of radical prostatectomy specimens. Arch Ital Urol Androl (2006) 0.79
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol (2002) 6.22
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
Efficient mapping of mendelian traits in dogs through genome-wide association. Nat Genet (2007) 5.99
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res (2002) 5.00
Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest (2011) 4.43
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood (2013) 4.17
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A (2008) 4.07
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res (2007) 3.82
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med (2015) 3.42
Global gene expression profiling of circulating tumor cells. Cancer Res (2005) 3.41
NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med (2006) 3.40
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem (2007) 3.38
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev (2010) 3.24
Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst (2003) 3.19
Recovery of corneal hysteresis after reduction of intraocular pressure in chronic primary angle-closure glaucoma. Am J Ophthalmol (2009) 3.15
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol (2006) 3.12
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Ameloblastin is a cell adhesion molecule required for maintaining the differentiation state of ameloblasts. J Cell Biol (2004) 3.00
Synthetic polymer coatings for long-term growth of human embryonic stem cells. Nat Biotechnol (2010) 2.89
Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med (2011) 2.83
CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem (2009) 2.81
The current state of hormonal therapy for prostate cancer. CA Cancer J Clin (2002) 2.74
Bone tissue engineering using polycaprolactone scaffolds fabricated via selective laser sintering. Biomaterials (2005) 2.66
Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood (2007) 2.65
Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer (2009) 2.64
Evolution of cooperation among tumor cells. Proc Natl Acad Sci U S A (2006) 2.63
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem (2003) 2.62
Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther (2008) 2.56
Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol (2007) 2.53
Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med (2009) 2.51
Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell (2005) 2.47
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 2.41
Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res (2010) 2.41
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell (2010) 2.37
Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res (2004) 2.36
Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood (2007) 2.35
Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res (2005) 2.32
Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res (2004) 2.31
Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res (2007) 2.31
Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol (2002) 2.31
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet (2013) 2.30
Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol (2005) 2.30
Genome-wide association study dissects the genetic architecture of oil biosynthesis in maize kernels. Nat Genet (2012) 2.25
Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol (2007) 2.21
Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia (2011) 2.21
Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol (2007) 2.16
Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res (2007) 2.14
Survival motor neuron function in motor axons is independent of functions required for small nuclear ribonucleoprotein biogenesis. J Neurosci (2006) 2.11
Morbidity of chemotherapy administration and satisfaction in breast cancer patients: a comparative study of totally implantable venous access device (TIVAD) versus peripheral venous access usage. World J Surg (2014) 2.06
CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia (2006) 2.05
Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev (2013) 2.05
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. Cancer (2007) 2.02
Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res (2003) 1.97
MT1-MMP-dependent control of skeletal stem cell commitment via a β1-integrin/YAP/TAZ signaling axis. Dev Cell (2013) 1.95
TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome. Hum Mutat (2006) 1.93
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev (2009) 1.93
CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia (2007) 1.91